 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Amarin Corporation plc (AMRN) is a pharmaceutical company.
The firm engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States.
The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels.
Amarin Corporation plc sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has a collaboration with Mochida Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Biologix FZCo, and HLS Therapeutics, Inc.
Shares have formed a bullish "cup and handle" following the compay's latest earnings report. On November 5th, Amarin reported a 3rd Quarter September 2019 loss of $0.01 per share on revenue of $112.4 million. The consensus estimate was a loss of $0.04 per share on revenue of $112.4 million. Revenue grew 103.2% on a year-over-year basis.
The company said it continues to expect 2019 revenue of $380.0 million to $420.0 million. The current consensus estimate is revenue of $418.8 million for the year ending December 31, 2019. Higher share prices are expected for this stock.
Entry Point: $22.50
Trading Range: $11.78 to $24.67
Stop Loss: $21.35
Target Price: $24.75
Closed at $21.00
